High frequency of AML1/RUNX1 point mutations in radiation-associated myelodysplastic syndrome around Semipalatinsk Nuclear Test Site

Journal of Radiation Research

Volumn 49, Issue 5, 2008, Pages 549-555

  Zharlyganova, Dinara ^a   Harada, Hironori ^a   Harada, Yuka ^a   Shinkarev, Sergey ^b   Zhumadilov, Zhaxybay ^c   Zhunusova, Aigul ^c   Tchaizhunusova, Naylya J ^d   Apsalikov, Kazbek N ^d   Kemaikin, Vadim ^e   Zhumadilov, Kassym ^a   Kawano, Noriyuki ^a   Kimura, Akiro ^a   Hoshi, Masaharu ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b FEDERAL BIOMEDICAL AGENCY OF RUSSIA   (Russian Federation)

^c SEMEY MEDICAL UNIVERSITY   (Kazakhstan)

^d KAZAKH SCIENTIFIC RESEARCH INSTITUTE FOR RADIATION MEDICINE AND ECOLOGY   (Kazakhstan)

^e City Oncological Clinic of Astana   (Kazakhstan)

Author keywords

AML1 point mutation; Myelodysplastic syndrome; Semipalatinsk nuclear test site

Indexed keywords

BOMBS (ORDNANCE); IONIZING RADIATION; RADIATION EFFECTS; RADIOTHERAPY;

ACUTE MYELOID LEUKEMIA; AML1 POINT MUTATION; ATOMIC BOMB SURVIVORS; BONE MARROW; HIGH FREQUENCY HF; MYELODYSPLASTIC SYNDROMES; POINT MUTATIONS; SEMIPALATINSK NUCLEAR TEST SITES; SOLID CANCER;

DISEASES;

EID: 52249103968     PISSN: 04493060     EISSN: 13499157     Source Type: Journal    
DOI: 10.1269/jrr.08040     Document Type: Article

References (33)

1. Mikhailov, V. N. (1996) Nuclear weapons tests and peaceful nuclear explosions in the USSR 1949-1990. Ministry of the Russian Federation on Atomic Energy and Ministry of Defense of the Russian Federation, Moscow.
2. Gordeev, K., Vasilenko, I., Lebedev, A., Bouville, A., Luckyanov, N., Simon, S. L., Stepanov, Y., Shinkarev, S. and Anspaugh, L. (2002) Fallout from nuclear tests: dosimetry in Kazakhstan. Radiat. Environ. Biophys. 41: 61-67.
3. Stepanenko, V. F., Hoshi, M., Bailiff, I. K., Ivannikov, A. I., Toyoda, S., Yamamoto, M., Simon, S. L., Matsuo, M., Kawano, N., Zhumadilov, Z., Sasaki, M. S., Rosenson, R. I. and Apsalikov, K. N. (2006) Around Semipalatinsk nuclear test site: progress of dose estimations relevant to the consequences of nuclear tests (a summary of 3rd Dosimetry Workshop on the Semipalatinsk nuclear test site area, RIRBM, Hiroshima University, Hiroshima, 9-11 of March, 2005). J. Radiat. Res. 47: A1-13.
4. Stepanenko, V. F., Hoshi, M., Yamamoto, M., Sakaguchi, A., Takada, J., Sato, H., Iaskova, E. K., Kolizshenkov, T. V., Kryukova, I. G., Apsalikov, K. N., Gusev, B. I. and Jungner, H. (2006) International intercomparison of retrospective luminescence dosimetry method: sampling and distribution of the brick samples from Dolon' village, Kazakhstan. J. Radiat. Res. 47: A15-21.
5. Zhumadilov, K, Ivannikov, A., Apsalikov, K. N., Zhumadilov, Z., Toyoda, S., Zharlyganova, D., Tieliewuhan, E., Endo, S., Tanaka, K, Miyazawa, C., Okamoto, T. and Hoshi, M. (2006) Radiation dose estimation by tooth enamel EPR dosimetry for residents of Dolon and Bodene. J. Radiat. Res. 47: A47-53.
6. Semioshkina, N. and Voigt, G. (2006) An overview on GSF activities at the Semipalatinsk Test Site, Kazakhstan. J. Radiat. Res. 47: A95-100.
7. Sakaguchi, A., Yamamoto, M., Hoshi, M., Imanaka, T., Apsalikov, K. N. and Gusev, B. I. (2006) Radiological situation in the vicinity of Semipalatinsk nuclear test site: Dolon, Mostik, Cheremushka and Budene settlements. J. Radiat. Res. 47: A101-116.
8. Gordeev, K, Shinkarev, S., Ilyin, L., Bouville, A., Hoshi, M., Luckyanov, N. and Simon, S. L. (2006) Retrospective dose assessment for the population living in areas of local fallout from the Semipalatinsk nuclear test site Part I: External exposure. J. Radiat. Res. 47: A129-136.
9. Simon, S. L., Beck, H. L., Gordeev, K, Bouville, A., Anspaugh, L. R., Land, C. E., Luckyanov, N. and Shinkarev, S. (2006) External dose estimates for Dolon village: application of the U.S./Russian joint methodology. J. Radiat. Res. 47: A143-147.
10. Gusev, B. I., Rosenson, R. I. and Abylkassimova, Z. N. (1998) The Semipalatinsk nuclear test site: a first analysis of solid cancer incidence (selected sites) due to test-related radiation. Radiat. Environ. Biophys. 37: 209-214.
11. Zhumadilov, Z., Gusev, B. I., Takada, J., Hoshi, M., Kimura, A., Hayakawa, N. and Takeichi, N. (2000) Thyroid abnormality trend over time in northeastern regions of Kazakstan, adjacent to the Semipalatinsk nuclear test site: a case review of pathological findings for 7271 patients. J. Radiat. Res. 41: 35-44.
12. Grosche, B. (2002) Semipalatinsk test site: introduction. Radiat. Environ. Biophys. 41: 53-55.
13. Bauer, S., Gusev, B. I., Pivina, L. M., Apsalikov, K. N. and Grosche, B. (2005) Radiation exposure due to local fallout from Soviet atmospheric nuclear weapons testing in Kazakhstan: solid cancer mortality in the Semipalatinsk historical cohort, 1960-1999. Radiat. Res. 164: 409-419.
14. Abylkassimova, Z., Gusev, B., Grosche, B., Bauer, S., Kreuzer, M. and Trott, K. (2000) Nested case-control study of leukemia among a cohort of persons exposed to ionizing radiation from nuclear weapon tests in kazakhstan (1949-1963). Ann. Epidemiol. 10: 479.
15. Ichimaru, M., Ishimaru, T. and Belsky, J. L. (1978) Incidence of leukemia in atomic bomb survivors belonging to a fixed cohort in Hiroshima and Nagasaki, 1950-71. Radiation dose, years after exposure, age at exposure, and type of leukemia. J. Radiat. Res. 19: 262-282.
16. Preston, D. L., Kusumi, S., Tomonaga, M., Izumi, S., Ron, E., Kuramoto, A., Kamada, N., Dohy, H., Matsuo, T., Matsui, T. and et al. (1994) Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987. Radiat. Res. 137: S68-97.
17. Nakanishi, M., Tanaka, K., Shintani, T., Takahashi, T. and Kamada, N. (1999) Chromosomal instability in acute myelo-cytic leukemia and myelodysplastic syndrome patients among atomic bomb survivors. J. Radiat. Res. 40: 159-167.
18. Kato, H. and Shimizu, Y. (1995) Cancer mortality rates in atomic bomb survivors. In: Effects of A-Bomb Radiation on the Human Body, Eds. Shigematsu, I., Ito, C., Kamada, N., Akiyama, M. and Sasaki, H., pp. 26-39. Bunkodo Co., Ltd., Tokyo.
19. Corey, S. J., Minden, M. D., Barber, D. L., Kantarjian, H., Wang, J. C. and Schimmer, A. D. (2007) Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer 7: 118-129.
20. Harada, H., Harada, Y., Tanaka, H., Kimura, A. and Inaba, T. (2003) Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. Blood 101: 673-680.
21. Kurokawa, M. (2006) AML1/Runx1 as a versatile regulator of hematopoiesis: regulation of its function and a role in adult hematopoiesis. Int. J. Hematol. 84: 136-142.
22. Harada, H., Harada, Y., Niimi, H., Kyo, T., Kimura, A. and Inaba, T. (2004) High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood 103: 2316-2324.
23. Pedersen-Bjergaard, J., Andersen, M. K., Christiansen, D. H. and Nerlov, C. (2002) Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood 99: 1909-1912.
24. Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A., Gralnick, H. R. and Sultan, C. (1982) Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. 51: 189-199.
25. Niimi, H., Harada, H., Harada, Y., Ding, Y., Imagawa, J., Inaba, T., Kyo, T. and Kimura. A. (2006) Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations. Leukemia 20: 635-644.
26. Bowen, D. T., Frew, M. E., Rollinson, S., Roddam, P. L., Dring, A., Smith, M. T., Langabeer, S. E. and Morgan, G. J. (2003) CYP1A1*2B (Val) allele is overrepresented in a subgroup of acute myeloid leukemia patients with poor-risk karyotype associated with NRAS mutation, but not associated with FLT3 internal tandem duplication. Blood 101: 2770-2774.
27. Pullarkat, V. A., Bueso-Ramos, C., Lai, R., Kroft, S., Wilson, C. S., Pullarkat, S. T., Bu, X., Thein, M., Lee, M. and Brynes, R. K. (2003) Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clin-icopathologic features and activating c-kit mutations. Am. J. Hematol. 73: 12-17.
28. Christiansen, D. H., Andersen, M. K. and Pedersen-Bjergaard, J. (2001) Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J. Clin. Oncol. 19: 1405-1413.
29. Kiyoi, H., Naoe, T., Nakano, Y., Yokota, S., Minami, S., Miyawaki, S., Asou, N., Kuriyama, K., Jinnai, I., Shimazaki, C., Akiyama, H., Saito, K., Oh, H., Motoji, T., Omoto, E., Saito, H., Ohno, R. and Ueda, R. (1999) Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 93: 3074-3080.
30. Yamamoto, Y., Kiyoi, H., Nakano, Y., Suzuki, R., Kodera, Y., Miyawaki, S., Asou, N., Kuriyama, K., Yagasaki, F., Shimazaki, C., Akiyama, H., Saito, K., Nishimura, M., Motoji, T., Shinagawa, K., Takeshita, A., Saito, H., Ueda, R., Ohno, R. and Naoe, T. (2001) Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97: 2434-2439.
31. Testa, A., Stronati, L., Ranaldi, R., Spano, M., Steinhausler, F., Gastberger, M., Hubmer, A., Ptitskaya, L. and Akhmetov, M. (2001) Cytogenetic biomonitoring carried out in a village (Dolon) adjacent to the Semipalatinsk nuclear weapon test site. Radiat. Environ. Biophys. 40: 125-129.
32. Taooka, Y., Takeichi, N., Noso, Y., Kawano, N., Apsalikov, K. N. and Hoshi, M. (2006) Increased T-cell receptor mutation frequency in radiation-exposed residents living near the Semipalatinsk nuclear test site. J. Radiat. Res. 47: A179-181.
33. Alipov, G., Ito, M., Prouglo, Y., Takamura, N. and Yamashita, S. (1999) Ret proto-oncogene rearrangement in thyroid cancer around Semipalatinsk nuclear testing site. Lancet 354: 1528-1529.